Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
ECOTRIN |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
OTC |
| Pharmacological Class |
|
Antiplatelet. |
| Generic Name |
|
Aspirin 81mg, 325mg, 500mg; e-c tabs. |
| Indications |
|
To reduce combined risk of death and nonfatal stroke after ischemic stroke or TIA. To reduce risk of vascular mortality in suspected acute MI. To reduce combined risk of death and nonfatal MI after MI or unstable angina pectoris. To reduce combined risk of MI and sudden death in chronic stable angina. Revascularization procedures. |
| Children |
|
Not recommended. |
| Adults |
|
Ischemic stroke and TIA: 50–325mg once daily. Suspected acute MI: 160–162.5mg once daily (start as soon as MI suspected) then for at least 30 days post-MI. Prevention of recurrent MI, unstable angina pectoris, chronic stable angina: 75–325mg once daily. Coronary artery bypass graft: 325mg once daily (start 6 hours after procedure) for 1 year. Percutaneous transluminal coronary angioplasty: 325mg 2 hours before surgery, then 160–325mg once daily. Carotid endarterectomy: 80mg once daily to 650mg twice daily (start before surgery). |
| Contraindications |
|
NSAID allergy. Viral infection in children and teenagers. 3rd trimester pregnancy. |
| Precautions |
|
History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy, nursing mothers: not recommended. |
| Interactions |
|
Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. |
| Adverse Reactions |
|
GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism. |
| How Supplied |
Tabs 81mg—36, 120
325mg—100, 250
500mg—60, 150 |
|
|
|
|
